ORTHO Regenerative Technologies $ORTH.ca $ORTIF is Using Proprietary Tech to Improve Surgery Success Rates and Seize a $5bn Market Opportunity

ORTHO Regenerative Technologies is a cutting-edge med tech firm that uses its proprietary RESTORE technology platform to dramatically improve the success rate of orthopedic and sports medicine surgeries.

• In layman’s terms, that means company has a wonder delivery platform that delivers biologics – drugs made from biological processes – to repair soft tissues in the human body.

The technology uses biologics derived from things like plasma and bone marrow concentrate to regenerate new tissue in various musculoskeletal conditions.

• This includes Wound Healing, Cartilage repair and Osteo-arthritis

So, how big is the market opportunity for Soft Tissue Repair? At least $5bn in the U.S. alone. This includes:

Rotator Cuff TEAR (which leads to shoulder dysfunction and pain):

• 4m patients in the U.S. alone
• 600,000 annual surgeries in the U.S. alone
• $600m+ market opportunity

Meniscus Tear Repair (which is painful and compromises knee function):

• There are 1.2m surgeries annually in U.S. alone
• $1bn+ market opportunity

Cartilage Lesions Repair (this is where lesions cause friction and pain):

• 1.2m detected lesions annually in U.S. alone
• 120,000 surgeries and a lack of options
• $1bn+ market opportunity

Get comfy for this insightful interview with Claude LeDuc, Ortho’s CEO.